This report covers recent developments in the health sector, including proposed US federal budget cuts affecting scientific ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

With pharmaceutical GLP-1 drugs like semaglutide in high demand, Metamorphx offers a plant-based alternative designed to ...

Novo Nordisk ( ($NVO) ) has risen by 10.56%. Read on to learn why. Novo Nordisk has seen a notable increase in its stock price, rising by 10.56% ...

Weight loss pills either reduce appetite, boost metabolism or block fat absorption. Most people lose 5% to 10% of their body ...

Sometimes, it makes sense to skip insurance and instead take advantage of a health savings account or flexible savings ...

SHOPPING: If you're ready to meet your weight goals, turn to Hims for personalized weight loss treatments that are ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

The WHO announced its plan to support GLP-1 weight-loss drugs, like Wegovy and Zepbound, to address the global obesity epidemic, according to Reuters.